RLTs

Mar 20, 2026

Summary Radioligand therapy is quickly establishing itself as a transformative force in oncology, with demand accelerating so rapidly that manufacturers are under pressure to scale up production. Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive lan...

Mar 09, 2026

Summary  Radioligand therapy is becoming a crucial component of cancer treatment. Approved radioligand therapy includes LUTATHERA (for GEP-NETs), XOFIGO, PLUVICTO (both for prostate cancer), and ZEVALIN (for follicular B-cell non-Hodgkin's lymphoma). Leading companies such as Novartis, Curium Pharma,...